Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Big vials of Alzheimer's drug could cost Medicare $336M
Medicare could be throwing away as much as $336 million worth of a costly Alzheimer's drug each year because the size of vials is too big, UCLA researchers estimate. Why it matters: The findings, published Monday in JAMA Internal Medicine,
Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
New Vial Size Could Save US Medicare Millions on Alzheimer's Breakthrough Drug Leqembi
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or lecanemab by simply introducing a new vial size that would reduce the amount of unused medication thrown away.
Changing Alzheimer's drug vial size might save big money for Medicare
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims.
FiercePharma
2d
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
The American Journal of Managed Care
2d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
5h
Experts label TGA’s decision to not register Alzheimer’s drug ‘extremely disappointing’
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
pharmaphorum
5d
In shock move, EU panel rejects Alzheimer's drug Leqembi
The CHMP also concluded that, after 18 months of treatment, the benefit seen with
Leqembi
on CDR-SB – a 1.21-point increase with the
drug
versus a 1.66-point rise with placebo – represented a ...
7d
Alzheimer’s treatments enter a new era
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
11h
on MSN
More kids having seizures after ingesting medications, illicit drugs
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
1d
on MSN
Kerala Man Infected With Rare Bacterial Disease, Murine Typhus; Here’s What You Should Know About It
A man from Kerala experienced severe body pain and fatigue upon seeking medical attention, he was diagnosed with rare ...
BioSpace
2d
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Medicare
Alzheimer's disease
Feedback